2020.08.20 Li Bowen's review was published in the international academic journal Drug Resist Updat

On August 20, 2020, Li Bowen, a student from our office, published "Surmounting Cancer Drug Resistance: New Insights from the Perspective of N6-methyladenosine RNA Modification." in the international academic journal Drug Resist Updat.

Tumor drug resistance is one of the most difficult problems in clinical practice, among which epigenetic modification plays an important role in the recurrence of tumor drug resistance. RNA N6-methyladenosine (m6A) modification, the most extensive of the RNA epigenetic modifications, has been discovered since the 1960s but has not attracted much interest from researchers. In 2011, researchers identified the m6A demethylase FTO, which proved that m6A was reversible and regulated. In the following nine years, the key molecules regulating m6A modification, such as reader, Writer and Eraser, were discovered. In recent years, it has been found that many key molecules of drug resistance have changed the modification level of m6A, and small molecule drugs targeting m6A have gradually moved from laboratory to early clinical trials, providing a new potential scheme for the treatment of drug resistance of tumors. In this paper, we systematically describe the different molecular mechanisms of m6A modification involved in tumor drug resistance, review the currently discovered small molecule drugs targeting m6A to reverse tumor drug resistance, and discuss the existing problems and prospects of m6A targeting to reverse tumor drug resistance. With the progress of science and technology and the efforts of researchers, we believe that the study of m6A modification will provide a new strategy for the treatment of cancer resistance, and benefit more cancer patients in the near future.